OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ARQ$2.6360

Arq Inc

Commodity ChemicalsVerified

Arq Inc's capital structure is characterized by a low debt-to-equity ratio of 0.17, indicating a conservative leverage position relative to its equity base. The company's liquidity position is assessed as medium, with a current ratio of 1.04 and negative free cash flow of -$49.97 million, suggesting potential short-term liquidity constraints. The price-to-book ratio of 0.67 implies that the company's market value is trading at a discount to its book value, which may reflect market concerns about its current profitability and future prospects. Profitability metrics for Arq Inc are weak, with a return on equity of -31.32% and a return on assets of -22.82%, both significantly below industry norms for commodity chemicals firms. The company reported a net loss of $52.61 million and an operating loss of $52.27 million, indicating a challenging operating environment. Gross profit of $33.53 million on $120.34 million in revenue suggests a gross margin of approximately 27.86%, which is below the typical gross margin for firms in the commodity chemicals industry. Arq Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases the company's exposure to regional economic fluctuations and industry-specific risks. The company's capital expenditures of -$9.11 million indicate a reduction in investment in long-term assets, which may signal a strategic shift or financial constraints. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the data. However, the negative operating cash flow of -$2.73 million and the absence of positive earnings suggest a lack of momentum in revenue generation and cost control. The company's ability to improve its financial performance will depend on its capacity to reduce operating losses and enhance profitability. Risk factors for Arq Inc include its negative net cash position after subtracting total debt, which could limit its ability to fund operations and invest in growth opportunities. The company's dilution risk is assessed as low, with no significant dilution potential identified in the data. However, the company's financial performance and liquidity position may necessitate future capital raising activities, which could lead to share dilution. Recent events and disclosures for Arq Inc include analyst price targets ranging from $3.00 to $6.50, with a mean price target of $4.20 and a median price target of $3.50. The mean recommendation from analysts is 1.80, indicating a generally positive outlook, with one strong-buy recommendation and four buy recommendations. These analyst sentiments suggest that while there is optimism about the company's potential, the current financial performance and market conditions present significant challenges.

30-day price · ARQ+0.24 (+9.6%)
Low$2.10High$2.78Close$2.73As of12 May, 00:00 UTC
Profile
CompanyArq Inc
TickerARQ.O
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Arq Inc is a chemical company that operates in the commodity chemicals industry, producing and selling chemical products for industrial applications.

Classification. Arq Inc is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with a confidence level of 0.92.

Arq Inc's capital structure is characterized by a low debt-to-equity ratio of 0.17, indicating a conservative leverage position relative to its equity base. The company's liquidity position is assessed as medium, with a current ratio of 1.04 and negative free cash flow of -$49.97 million, suggesting potential short-term liquidity constraints. The price-to-book ratio of 0.67 implies that the company's market value is trading at a discount to its book value, which may reflect market concerns about its current profitability and future prospects. Profitability metrics for Arq Inc are weak, with a return on equity of -31.32% and a return on assets of -22.82%, both significantly below industry norms for commodity chemicals firms. The company reported a net loss of $52.61 million and an operating loss of $52.27 million, indicating a challenging operating environment. Gross profit of $33.53 million on $120.34 million in revenue suggests a gross margin of approximately 27.86%, which is below the typical gross margin for firms in the commodity chemicals industry. Arq Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases the company's exposure to regional economic fluctuations and industry-specific risks. The company's capital expenditures of -$9.11 million indicate a reduction in investment in long-term assets, which may signal a strategic shift or financial constraints. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the data. However, the negative operating cash flow of -$2.73 million and the absence of positive earnings suggest a lack of momentum in revenue generation and cost control. The company's ability to improve its financial performance will depend on its capacity to reduce operating losses and enhance profitability. Risk factors for Arq Inc include its negative net cash position after subtracting total debt, which could limit its ability to fund operations and invest in growth opportunities. The company's dilution risk is assessed as low, with no significant dilution potential identified in the data. However, the company's financial performance and liquidity position may necessitate future capital raising activities, which could lead to share dilution. Recent events and disclosures for Arq Inc include analyst price targets ranging from $3.00 to $6.50, with a mean price target of $4.20 and a median price target of $3.50. The mean recommendation from analysts is 1.80, indicating a generally positive outlook, with one strong-buy recommendation and four buy recommendations. These analyst sentiments suggest that while there is optimism about the company's potential, the current financial performance and market conditions present significant challenges.
Key takeaways
  • Arq Inc is operating at a net loss with a return on equity of -31.32% and a return on assets of -22.82%.
  • The company's liquidity position is medium, with a current ratio of 1.04 and negative free cash flow of -$49.97 million.
  • Arq Inc's revenue is concentrated in a single business segment, increasing its exposure to industry-specific risks.
  • Analysts have a generally positive outlook, with a mean price target of $4.20 and a median price target of $3.50.
  • The company's capital expenditures have decreased, indicating a potential strategic shift or financial constraints.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$120.3M
Gross profit$33.5M
Operating income-$52.3M
Net income-$52.6M
R&D
SG&A
D&A
SBC
Operating cash flow-$2.7M
CapEx-$9.1M
Free cash flow-$50.0M
Total assets$230.6M
Total liabilities$62.6M
Total equity$168.0M
Cash & equivalents$6.6M
Long-term debt$28.5M
Valuation
Market price$2.63
Market cap$112.8M
Enterprise value$134.7M
P/E
Reported non-GAAP P/E
EV/Revenue1.1
EV/Op income
EV/OCF
P/B0.7
P/Tangible book0.7
Tangible book$168.0M
Net cash-$21.9M
Current ratio1.0
Debt/Equity0.2
ROA-22.8%
ROE-31.3%
Cash conversion5.0%
CapEx/Revenue-7.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricARQActivity
Op margin-43.4%5.5% medp25 -0.0% · p75 10.8%bottom quartile
Net margin-43.7%4.1% medp25 0.1% · p75 8.8%bottom quartile
Gross margin27.9%20.5% medp25 12.4% · p75 29.7%above median
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-7.6%-6.2% medp25 -13.4% · p75 -2.6%below median
Debt / equity17.0%37.1% medp25 10.3% · p75 82.0%below median
Observations
IR observations
Mean price target4.20 USD
Median price target3.50 USD
High price target6.50 USD
Low price target3.00 USD
Mean recommendation1.80 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count4.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.08 USD
Last actual EPS-0.15 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 14:43 UTC#57c4fd88
Market quoteclose USD 2.59 · shares 0.04B diluted
no public URL
2026-05-16 14:44 UTC#bd847197
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 09:39 UTCJob: 65160fc5